Answers are grounded in this paper and cite their sources.
This review explores cisplatin's mechanisms, challenges like drug resistance, and advanced therapies to enhance outcomes.
Cisplatin is a commonly used platinum-based chemotherapeutic agent that is effective in treating cancers such as lung, ovarian, and testicular malignancies; it primarily acts by binding to DNA, forming adducts, and inhibiting cell division while inducing apoptosis through both intrinsic and extrinsic pathways; it also generates oxidative stress via reactive oxygen species, contributing to tumour cell death; additionally, cisplatin influences important cellular signalling pathways, with nephrotoxicity being the most common dose-limiting toxicity. Drug resistance is still a significant problem because of decreased drug accumulation, improved DNA repair, and drug inactivation; combination therapies with other anticancer medications have been used to improve treatment outcomes; sophisticated drug delivery systems like nanoparticles and liposomal formulations help enhance efficacy and reduce side effects; and future approaches like targeted therapy and artificial intelligence-based optimisation aim to improve safety, precision, and overall therapeutic effectiveness.
No takes yet. Share an insight, caveat, or question.
Kestin K. Sabu1, Dhanush Kumar S.1, Kirthiga A.1, Dr. Arya M. S.2*, Dr. Amal A.2* (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: